Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis
ConclusionsWhen compared with FGL, patients receiving OCR showed greater suppression of focal MRI lesions accumulation and lower cortical and deep grey matter volume loss. (Source: Journal of Neurology)
Source: Journal of Neurology - January 30, 2024 Category: Neurology Source Type: research
Unraveling the Role of the Glycogen Synthase Kinase-3 β, Bruton's Tyrosine Kinase, and Sphingosine 1 Phosphate Pathways in Multiple Sclerosis
Endocr Metab Immune Disord Drug Targets. 2024 Jan 26. doi: 10.2174/0118715303261413231117113707. Online ahead of print.ABSTRACTInflammation, demyelination, and neurodegeneration are symptoms of the central nervous system (CNS) condition known as Multiple sclerosis (MS). Due to its crucial function in controlling immune cell activation and inflammation, the glycogen synthase kinase-3β (GSK3β), Bruton's tyrosine kinase (BTK), and Sphingosine 1 phosphate (S1P) signaling pathway have become a viable target for the therapy of MS. The GSK-3β signaling system, which controls several biological target processes, including cell ...
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - January 29, 2024 Category: Endocrinology Authors: Rupali Mohite Sankalp Gharat Gaurav Doshi Source Type: research
Unraveling the Role of the Glycogen Synthase Kinase-3 β, Bruton's Tyrosine Kinase, and Sphingosine 1 Phosphate Pathways in Multiple Sclerosis
Endocr Metab Immune Disord Drug Targets. 2024 Jan 26. doi: 10.2174/0118715303261413231117113707. Online ahead of print.ABSTRACTInflammation, demyelination, and neurodegeneration are symptoms of the central nervous system (CNS) condition known as Multiple sclerosis (MS). Due to its crucial function in controlling immune cell activation and inflammation, the glycogen synthase kinase-3β (GSK3β), Bruton's tyrosine kinase (BTK), and Sphingosine 1 phosphate (S1P) signaling pathway have become a viable target for the therapy of MS. The GSK-3β signaling system, which controls several biological target processes, including cell ...
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - January 29, 2024 Category: Drugs & Pharmacology Authors: Rupali Mohite Sankalp Gharat Gaurav Doshi Source Type: research
Analysis of seroconversion following COVID-19 vaccination among multiple sclerosis patients treated with disease-modifying therapies in Poland
CONCLUSIONS AND CLINICAL IMPLICATIONS: Our study shows that, in PwMS receiving immunomodulatory therapy, the immune response to vaccination is generally excellent. Even in immunosuppressive patients, seroconversion is satisfactory.PMID:38251955 | DOI:10.5603/pjnns.96425 (Source: Neurologia i Neurochirurgia Polska)
Source: Neurologia i Neurochirurgia Polska - January 22, 2024 Category: Neurology Authors: Aleksandra Podlecka-Pi ętowska Janusz Sierdzi ński Monika Nojszewska Jakub Stawicki Halina Bartosik-Psujek Beata Lech Ma łgorzata Popiel Adam Perenc Alina Ku łakowska Agata Czarnowska Joanna Kulikowska Katarzyna Kapica-Topczewska Anna Jamr óz-Wiśnie Source Type: research
Plasma antioxidant potential measured by total radical trapping antioxidant parameter in a cohort of multiple sclerosis patients
ConclusionOur findings suggest that lower plasma antioxidant potential is linked to more severe disability measured by EDSS scores. Patients treated with NTZ and FTY had reduced antioxidant power, which might be influenced by the active MS disease rather than the treatments themselves. The study reveals a strong positive correlation between UA levels and TRAP, particularly among women. However, men on average had better antioxidant potential than women. Neither the disease type nor the duration influences TRAP levels. While serving as a marker of antioxidant potential, plasma TRAP in MS patients does not reliably reflect o...
Source: Brain and Behavior - January 18, 2024 Category: Neurology Authors: Marge Kartau,
Joonas Kartau,
Marjatta Pohja,
Auli Verkkoniemi ‐Ahola Tags: ORIGINAL ARTICLE Source Type: research
Recurrent tumefactive demyelination under fingolimod treatment
(Source: Neurological Sciences)
Source: Neurological Sciences - January 15, 2024 Category: Neurology Source Type: research
Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study
Conclusions
Early relapses and substantial MRI activity in the first year of treatment are associated with worse short-term outcomes in patients treated with some of the oral DMTs. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - January 11, 2024 Category: Neurosurgery Authors: Ruggieri, S., Prosperini, L., Al-Araji, S., Annovazzi, P. O., Bisecco, A., Ciccarelli, O., De Stefano, N., Filippi, M., Fleischer, V., Evangelou, N., Enzinger, C., Gallo, A., Garjani, A., Groppa, S., Haggiag, S., Khalil, M., Lucchini, M., Mirabella, M., M Tags: Multiple sclerosis Source Type: research
Early postpartum treatment strategies and early postpartum relapses in women with active multiple sclerosis
Conclusion
In active MS, an early postpartum treatment strategy should be determined well before delivery. Natalizumab/fingolimod-strategy reduced postpartum relapse hazard from month 3, but none diminished the early postpartum relapse hazard. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - January 11, 2024 Category: Neurosurgery Authors: Haben, S., Ciplea, A. I., Tokic, M., Timmesfeld, N., Thiel, S., Gold, R., Langer-Gould, A. M., Hellwig, K. Tags: JNNP Patients' choice, Open access Multiple sclerosis Source Type: research
Validation of a Novel Method to Assess the Clinical Quality of Information in Pregnancy-Related Pharmacovigilance Case Reports: A ConcePTION Project
ConclusionsThe tool described in this study using the presence and relevance of elements of information is the first designed, validated and standardised method for the assessment of the quality of information of case reports in pregnancy pharmacovigilance data. This method confers less inter-rater variability compared with a quality assessment by experts of pregnancy-related pharmacovigilance data. (Source: Drug Safety)
Source: Drug Safety - January 6, 2024 Category: Drugs & Pharmacology Source Type: research
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
CONCLUSIONS: We are highly confident that, compared to placebo, two-year treatment with natalizumab, cladribine, or alemtuzumab decreases relapses more than with other DMTs. We are moderately confident that a two-year treatment with natalizumab may slow disability progression. Compared to those on placebo, people with RRMS treated with most of the assessed DMTs showed a higher frequency of treatment discontinuation due to AEs: we are moderately confident that this could happen with fingolimod, teriflunomide, interferon beta-1a, laquinimod, natalizumab and daclizumab, while our certainty with other DMTs is lower. We are als...
Source: Cochrane Database of Systematic Reviews - January 4, 2024 Category: General Medicine Authors: Marien Gonzalez-Lorenzo Ben Ridley Silvia Minozzi Cinzia Del Giovane Guy Peryer Thomas Piggott Matteo Foschi Graziella Filippini Irene Tramacere Elisa Baldin Francesco Nonino Source Type: research
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
CONCLUSIONS: We are highly confident that, compared to placebo, two-year treatment with natalizumab, cladribine, or alemtuzumab decreases relapses more than with other DMTs. We are moderately confident that a two-year treatment with natalizumab may slow disability progression. Compared to those on placebo, people with RRMS treated with most of the assessed DMTs showed a higher frequency of treatment discontinuation due to AEs: we are moderately confident that this could happen with fingolimod, teriflunomide, interferon beta-1a, laquinimod, natalizumab and daclizumab, while our certainty with other DMTs is lower. We are als...
Source: Cochrane Database of Systematic Reviews - January 4, 2024 Category: General Medicine Authors: Marien Gonzalez-Lorenzo Ben Ridley Silvia Minozzi Cinzia Del Giovane Guy Peryer Thomas Piggott Matteo Foschi Graziella Filippini Irene Tramacere Elisa Baldin Francesco Nonino Source Type: research
Letter to the editors: Development of malignant melanoma and squamous cell carcinoma in a patient receiving fingolimod treatment
(Source: Neurological Sciences)
Source: Neurological Sciences - January 1, 2024 Category: Neurology Source Type: research
Purmorphamine, a Smo-Shh/Gli Activator, Promotes Sonic Hedgehog-Mediated Neurogenesis and Restores Behavioural and Neurochemical Deficits in Experimental Model of Multiple Sclerosis
Neurochem Res. 2023 Dec 30. doi: 10.1007/s11064-023-04082-9. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a pathological condition characterized by the demyelination of nerve fibers, primarily attributed to the destruction of oligodendrocytes and subsequent motor neuron impairment. Ethidium bromide (EB) is a neurotoxic compound that induces neuronal degeneration, resulting in demyelination and symptoms resembling those observed in experimental animal models of multiple sclerosis (MS). The neurotoxic effects induced by EB in multiple sclerosis (MS) are distinguished by the death of oligodendrocytes, degradation ...
Source: Neurochemical Research - December 30, 2023 Category: Neuroscience Authors: Aradhana Prajapati Sidharth Mehan Zuber Khan Swesha Chhabra Ghanshyam Das Gupta Source Type: research
Purmorphamine, a Smo-Shh/Gli Activator, Promotes Sonic Hedgehog-Mediated Neurogenesis and Restores Behavioural and Neurochemical Deficits in Experimental Model of Multiple Sclerosis
Neurochem Res. 2023 Dec 30. doi: 10.1007/s11064-023-04082-9. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is a pathological condition characterized by the demyelination of nerve fibers, primarily attributed to the destruction of oligodendrocytes and subsequent motor neuron impairment. Ethidium bromide (EB) is a neurotoxic compound that induces neuronal degeneration, resulting in demyelination and symptoms resembling those observed in experimental animal models of multiple sclerosis (MS). The neurotoxic effects induced by EB in multiple sclerosis (MS) are distinguished by the death of oligodendrocytes, degradation ...
Source: Neurochemical Research - December 30, 2023 Category: Neuroscience Authors: Aradhana Prajapati Sidharth Mehan Zuber Khan Swesha Chhabra Ghanshyam Das Gupta Source Type: research
